Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling.

IF 1.6 Q3 ALLERGY

Asia Pacific Allergy Pub Date : 2023-03-01 DOI:10.5415/apallergy.0000000000000020

Hugo W F Mak, Elsie T S Chan, Jackie S H Yim, Elaine Lee, Dorothy L Y Lam, Valerie Chiang, Philip H Li

{"title":"Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling.","authors":"Hugo W F Mak, Elsie T S Chan, Jackie S H Yim, Elaine Lee, Dorothy L Y Lam, Valerie Chiang, Philip H Li","doi":"10.5415/apallergy.0000000000000020","DOIUrl":null,"url":null,"abstract":"The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known.Objective: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q.Methods: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre-post comparison.Results: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939-0.971) and test-retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969-0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre-post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen's d = 0.964; P < 0.001), reflecting improvement in HRQoL.Conclusion: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients' HRQoL. Future larger-scale studies are warranted to corroborate our findings.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 1","pages":"3-9"},"PeriodicalIF":1.6000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/e3/pa9-13-03.PMC10166238.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known.

Objective: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q.

Methods: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre-post comparison.

Results: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939-0.971) and test-retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969-0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre-post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen's d = 0.964; P < 0.001), reflecting improvement in HRQoL.

Conclusion: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients' HRQoL. Future larger-scale studies are warranted to corroborate our findings.

Abstract Image

查看原文本刊更多论文

中药超敏反应生活质量问卷的验证:去标签的作用。

药物超敏反应生活质量问卷(DrHy-Q)目前没有中文版本。此外，青霉素过敏(PA)是一个全球性的公共卫生挑战，去除不真实PA的标签可以改善临床和经济结果。然而，其对健康相关生活质量(HRQoL)的影响仍然知之甚少。目的:翻译并验证DrHy-Q的中文版，并利用DrHy-Q探讨PA去标签对HRQoL的影响。方法:翻译一份中文DrHy-Q，并由有药物过敏标签的患者填写，进行心理测试验证。之后，另一组患者在PA检查前后完成中文DrHy-Q，进行前后比较。结果:共研究了130例患者。63例患者(女性79.4%;中位年龄= 59±15岁)完成中国DrHy-Q进行验证(平均得分= 38.9±23.5)。具有良好的内部一致性(Cronbach α = 0.956;95%置信区间[CI]， 0.939 ~ 0.971)和重测信度(类内相关系数= 0.993 [95% CI, 0.969 ~ 0.998])。因子分析以其一维结构证实了构念效度。发散效度是建立的，因为只有2 (9)SF-36量表与DrHy-Q呈弱负相关。多药联合用药患者的DrHy-Q评分明显高于单药联合用药患者(42.0±22.5 vs 28.7±24.4;P = 0.038)，具有区分效度。随后又有67例患者(73.1%为女性;中位年龄= 56±15岁)接受了PA调查，并完成了DrHy-Q前的调查。DrHy-Q评分显著下降(40.8±21.7 vs 26.6±22.5;Cohen’s d = 0.964;P < 0.001)，反映HRQoL的改善。结论:中国DrHy-Q法是一种可靠、有效的HRQoL评价方法。PA去标签显著改善患者HRQoL。未来有必要进行更大规模的研究来证实我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia Pacific Allergy ALLERGY-

CiteScore

2.50

自引率

5.90%

发文量

期刊介绍： Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.